The mTOR pathway has long been a target of antiepileptic research due to genetic forms of epilepsy with mutations within the mTOR pathway (mammalian target of rapamycin; e.g., tuberous sclerosis 1/2 (TSC1/2) and phosphatase and tensin homolog (PTEN); [75,76]). The gene discussed is PTEN; the disease is epilepsy.